Accenture PLC Cl A Stock Rises 6.0%, Outperforms Peers
Dow Jones2026/10/08 20:33This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Accenture PLC Cl A rallied 6.0% to $208.36 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.1% to 51,231.64 and the S&P 500 Index falling 0.5% to 7,765.36. This was the stock's second consecutive day of gains. Accenture PLC Cl A closed 28.4% below its 52-week high of $291.09, which the company reached on January 14th. The stock outperformed some of its peers, as International Business Machines Corp. rose 2.8% to $226.61, Automatic Data Processing Inc. rose 2.5% to $270.73, and Cognizant Technology Solutions Corp. rose 5.15% to $60.01. Trading volume totaled 12.0 million, compared to the 50-day average of 6.2 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 08, 2026 16:33 ET (20:33 GMT)
This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Accenture PLC Cl A rallied 6.0% to $208.36 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.1% to 51,231.64 and the S&P 500 Index falling 0.5% to 7,765.36.
This was the stock's second consecutive day of gains.
Accenture PLC Cl A closed 28.4% below its 52-week high of $291.09, which the company reached on January 14th.
The stock outperformed some of its peers, as International Business Machines Corp. rose 2.8% to $226.61, Automatic Data Processing Inc. rose 2.5% to $270.73, and Cognizant Technology Solutions Corp. rose 5.15% to $60.01.
Trading volume totaled 12.0 million, compared to the 50-day average of 6.2 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 08, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 2-BP reports the highest net profit in at least five years
AstraZeneca (AZN.US) Q3 profit growth surpasses expectations, driven mainly by oncology drugs
AstraZeneca (AZN.US) released its Q3 2026 results on October 30th. At constant exchange rates (CER), total revenue for the quarter increased by 7% year-on-year to $16.209 billions.
BP.US Q3 profits soar to 18-year high: Refining business becomes 'money-printing machine', CEO's reforms encounter strong tailwind
Benefiting from a surge in refining profit margins, BP's quarterly profit jumped to its highest level in 18 years.
Australian Dollar: Bias shifts back to neutral against US Dollar – UOB
Crypto prices
More
